Spinethera

March 9, 2022

SpineThera to Present at WVSIPP Incube Meeting in Conjunction with ASPN Think Tank

Medical Alley, Minnesota, united states, March 9, 2022 – SpineThera, Inc., a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for treatment of lumbar radiculopathy) announced today that Jeff Missling, Chief Executive Officer, will be presenting at the InCube meeting hosted by the West Virginia Society of Interventional Pain Physicians (WVSIPP) in Nashville, TN on March 13, 2022. InCube is being held in conjunction with the American Society of Pain and Neuroscience (ASPN) Think Tank meeting.

Jeff Missling, CEO, stated, “We thank Dr. Rudy Malayil, President of WVSIPP, for the invitation to present at the Incube meeting, a showcase of emerging companies with novel approaches addressing pain. SpineThera’s SX600 utilizes SpineThera’s proprietary micro-suspension platform technology that enables a highly concentrated injection of sustained-release formulations. Its application in lumbar radiculopathy has the potential to provide longer-term pain relief from a single injection. I look forward to presenting our technology to this group of thought leaders at the InCube meeting.”

###

About SpineThera
SpineThera is a clinical stage pharmaceutical company working to improve the lives of patients by creating injectable drugs utilizing its proprietary and differentiated sustained-release platform technology. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. The company’s lead investigational drug product, SX600, is a novel formulation of dexamethasone being developed for lumbar radiculopathy. SpineThera, Inc., is based is Medical Alley, Minnesota, the global epicenter of health innovation and care. SpineThera Australia Pty Ltd is a wholly owned subsidiary of SpineThera, Inc., and is the sponsor of the SALIENT study.

Press Contact
info@spinethera.com

‍

Previous Article

Next Article 

SPINETHERA Awarded $5 Million
Grant From Department of Defence

No Previous Article

No Next Article

November 25, 2019

SpineThera announces first patient dosed in salient phase 1/2 clinical study sx600, an investigational non-opioid epidural steroid injection is being evaluated for the treatment of sciatica

MEDICAL ALLEY, Minnesota. – November 25, 2019 –SpineThera, Inc., and its subsidiary SpineThera Australia Pty Ltd, announced today the first dose has been administered in the SALIENT (Safety and Efficacy of SX600 Administered by Lumbosacral Transforaminal Epidural Injection for Radicular Pain) Phase 1/2 clinical study of SX600, a non-opioid epidural steroid injection in development for the treatment of sciatica.



August 22, 2019

SpineThera receives u.s. patent covering sustained-release injectable corticosteroid, sx600, a non-opioid drug in development for low back pain

SpineThera’s clinical development program for SX600 will evaluate sustained-release, injectable treatment options for pain in and near the spine Minneapolis, MN – August 22, 2019 - SpineThera, Inc., a privately held, clinical stage pharmaceutical company, announced today that the United States Patent and Trademark Office has issued Patent 10,350,222 related to its non-opioid, sustained-release drug technology.



October 22, 2018

Purdue Pharma L.P. Enters into Exclusive Option Agreement to Acquire SpineThera, Inc. and Its Non-Opioid Product in Development for Epidural Steroid Injection for the Treatment of Low Back Pain

Purdue will support SpineThera’s clinical development program to evaluate sustained-release, injectable treatment options for pain in and near the spine October 22, 2018 03:07 PM Eastern Daylight Time. STAMFORD, Conn. & PLYMOUTH, Minn.--(BUSINESS WIRE)--Purdue Pharma L.P. and SpineThera, Inc. today announced that the companies have entered into an agreement that provides Purdue the exclusive option to acquire SpineThera, Inc. and gain worldwide rights to its products and technology platforms, including lead asset SX600, a novel dexamethasone containing microsphere that is in development for epidural administration for low back pain. This technology has potential for development of non-opioid treatments for acute and chronic pain.



SpineThera to Present at WVSIPP Incube Meeting in Conjunction with ASPN Think Tank

SpineThera to Present at WVSIPP Incube Meeting in Conjunction with ASPN Think Tank

SpineThera announces first patient dosed in salient phase 1/2 clinical study sx600, an investigational non-opioid epidural steroid injection is being evaluated for the treatment of sciatica

SpineThera receives u.s. patent covering sustained-release injectable corticosteroid, sx600, a non-opioid drug in development for low back pain

Purdue Pharma L.P. Enters into Exclusive Option Agreement to Acquire SpineThera, Inc. and Its Non-Opioid Product in Development for Epidural Steroid Injection for the Treatment of Low Back Pain

Proven health impact